Inlexzo price?

See the DrugPatentWatch profile for Inlexzo

How much does Inlexzo cost?
Inlexzo’s list price in the United States is about $9,900 per month, or roughly $118,800 per year for the standard dosing regimen. [1]

What drives that price?
The cost reflects the drug’s complex production process, its status as a first‑in‑class immunotherapy for metastatic melanoma, and the manufacturer’s investment in clinical development.

Will insurance cover it?
Most large commercial plans and Medicare Part D will cover Inlexzo, but the out‑of‑pocket amount depends on the patient’s specific plan. Copay tiers can vary, so patients should check with their insurer.

How does Inlexzo compare to other melanoma treatments?
Keytruda (pembrolizumab) and Opdivo (nivolumab) are priced similarly, ranging from $8,000 to $10,000 per month. Inlexzo’s price falls within that same bracket.

Are there patient assistance programs?
Yes. The manufacturer offers a patient assistance program that may cover costs for qualifying patients who cannot afford the drug. Details are on the drug’s website.

Can the price drop after patent expiry?
Biosimilars can enter the market after the original patent expires. If a biosimilar becomes available, the price could drop by 20–30 %, depending on competition.

What if I’m on a pharmacy benefit manager (PBM) plan?
PBMs often negotiate rebates. The net price paid by the payer could be lower than the list price, but the exact figure varies by contract.

Is there a wholesale acquisition cost (WAC) to consider?
Yes. The WAC is the standard reference price set by the manufacturer, which is the figure used for most pricing comparisons. Inlexzo’s WAC is the $9,900 per month figure.

When should I check for price updates?
Manufacturers sometimes adjust prices annually. Review the drug’s pricing page or contact the manufacturer’s customer service each year for the latest figures.

Do clinicians prescribe Inlexzo only when other options fail?
Inlexzo is approved as a first‑line therapy for patients with metastatic melanoma that expresses a BRAF mutation. It is not reserved for later lines of treatment.

Can I get a discount card or savings program?
The manufacturer’s savings program offers a discount card that can reduce the out‑of‑pocket cost for patients with commercial insurance or Medicare Part D coverage.

Sources
[1] DrugPatentWatch.com – Inlexzo pricing information (https://www.drugpatentwatch.com/inlexzo/price)